Ong ACM, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int. 2005;67(4):1234–47.

Article  PubMed  CAS  Google Scholar 

Iglesias CG, Torres VE, Offord KP, Holley KE, Beard CM, Kurland LT. Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935–1980. Am J Kidney Dis. 1983;2(6):630–9.

Article  PubMed  CAS  Google Scholar 

Solazzo A, Testa F, Giovanella S, Busutti M, Furci L, Carrera P, et al. The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS ONE. 2018;13(1):e0190430.

Article  PubMed  PubMed Central  Google Scholar 

Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dialysis Transplant. 2017;32(8):1356–63.

Google Scholar 

Neumann HP, Jilg C, Bacher J, Nabulsi Z, Malinoc A, Hummel B, et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dialysis Transplant. 2013;28(6):1472–87.

Article  CAS  Google Scholar 

Rossetti S, Hopp K, Sikkink RA, Sundsbak JL, Lee YK, Kubly V, et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol. 2012;23(5):915–33.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, et al. Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(9):2872–84.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006–13.

Article  PubMed  PubMed Central  Google Scholar 

Peters DJ, Sandkuijl LA. Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol. 1992;97:128–39.

Article  PubMed  CAS  Google Scholar 

Hwang Y-H, Conklin J, Chan W, Roslin NM, Liu J, He N, et al. Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(6):1861–8.

Article  PubMed  CAS  Google Scholar 

Harris PC, Torres VE. Polycystic kidney disease, autosomal dominant. 2018.

Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJ, Torres VE. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50.

Article  PubMed  PubMed Central  Google Scholar 

Ong AC, Devuyst O, Knebelmann B, Walz G. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385(9981):1993–2002.

Article  PubMed  Google Scholar 

Lavu S, Vaughan LE, Senum SR, Kline TL, Chapman AB, Perrone RD, et al. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 2020;5(15):e138724.

Article  PubMed  PubMed Central  Google Scholar 

Oberdhan D, Cole JC, Krasa HB, Cheng R, Czerwiec FS, Hays RD, et al. Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-life instrument. Am J Kidney Dis. 2018;71(2):225–35.

Article  PubMed  Google Scholar 

Suwabe T, Ubara Y, Mise K, Kawada M, Hamanoue S, Sumida K, et al. Quality of life of patients with ADPKD—Toranomon PKD QOL study: cross-sectional study. BMC Nephrol. 2013;14(1):179.

Article  PubMed  PubMed Central  Google Scholar 

Gittus M, Harris T, Ong AC. Patient perspectives on ADPKD. Adv Kidney Dis Health. 2023;30(3):294–302.

Article  PubMed  Google Scholar 

Hoover E, Holliday V, Merullo N, Oberdhan D, Perrone RD, Rusconi C, et al. Pain and Health-related quality of life in autosomal dominant polycystic kidney disease: results from a National Patient-Powered Registry. Kidney Med. 2024;6(5):100813.

Article  PubMed  PubMed Central  Google Scholar 

Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol. 2014;25(1):18–32.

Article  PubMed  CAS  Google Scholar 

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–18.

Article  PubMed  PubMed Central  CAS  Google Scholar 

National Institute for Health and Care Excellence. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358). 2015.

Scottish Medicines Consortium. Tolvaptan (SMC No. 1114/1115). 2016.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4: 4 trial. Nephrol Dialysis Transplant. 2018;33(3):477–89.

Article  CAS  Google Scholar 

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930–42.

Article  PubMed  CAS  Google Scholar 

Torres VE, Gansevoort RT, Chapman AB, Perrone RD, Ouyang J, Lee J, et al. A Post Hoc Analysis of Tolvaptan (TOL) efficacy and safety in slowing rate of renal function decline in subjects with very late-stage autosomal Dominant polycystic kidney disease (ADPKD): PO1534. J Am Soc Nephrol. 2020;31(10S):490.

Article  Google Scholar 

Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrology: JASN. 2015;26(1):160.

Article  PubMed  CAS  Google Scholar 

Cornec-Le Gall E, Audrézet M-P, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrology: JASN. 2016;27(3):942.

Article  PubMed  Google Scholar 

Ong AC. Tolvaptan slows disease progression in late-stage ADPKD. Nat Rev Nephrol. 2018;14(3):146–8.

Article  Google Scholar 

Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrology: CJASN. 2018;13(8):1153.

Article  CAS  Google Scholar 

McGill RL, Saunders MR, Hayward AL, Chapman AB. Health disparities in autosomal dominant polycystic kidney disease (ADPKD) in the United States. Clin J Am Soc Nephrol. 2022;17(7):976–85.

Article  PubMed  PubMed Central  Google Scholar 

Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrology: JASN. 2018;29(10):2458.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pei Y, Hwang Y-H, Conklin J, Sundsbak JL, Heyer CM, Chan W, et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J Am Soc Nephrology: JASN. 2015;26(3):746.

Article  PubMed  CAS  Google Scholar 

Pei Y, Watnick T. Diagnosis and screening of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17(2):140–52.

Article  PubMed  PubMed Central  Google Scholar 

Chebib FT, Torres VE. Autosomal Dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67(5):792–810.

Article  PubMed  Google Scholar 

NHS England. The structure of the NHS Genomic Medicine Service 2023. Available from: